In the Western world, LinkedIn is a staple for many recruitment professionals. It has proven to be a powerful tool for networking, talent sourcing and job postings. But in Japan, people don’t use LinkedIn very much.Here’s why LinkedIn isn’t popular…
HOME > ACADEMIA
ACADEMIA
- Genome Sequencing Study of Biliary Tract Cancer Suggests Effectiveness of Immune Checkpoint Therapy: National Cancer Center
August 12, 2015
- St. Marianna Univ. Hospital Introduces Tougher Rules for Adopting New Drugs with Emphasis on Cost, Efficacy, and Safety
July 28, 2015
- PD-L1 Expression Key to Decide Whether to Combine Opdivo, Yervoy: Oncologist
July 21, 2015
- Japan, US Oncologists Exchange Barbs over Opdivo Costs
July 21, 2015
- Japan Lung Cancer Society Petitions Health Minister for Early Approval of AZ’s AZD9291 for EGFR-TKI-Resistant NSCLC
July 8, 2015
- NCC Starts PI Study of Nucleic Acid Drug in Treatment-Resistant Locally Advanced or Recurrent Breast Cancer
July 8, 2015
- JSGM to Issue Policy Proposal after MHLW Sets New Target for Generic Market Share
June 17, 2015
- AGs “Will Energize the Generic Drug Market”: Prof. Sakamaki
June 17, 2015
- MHLW Official Urges Generic Drug Makers to Expand into Overseas Markets
June 17, 2015
- MHLW Official Restates Difficulty of Moving Up Timeline to Attain 80% Generic Share
June 16, 2015
- Tiotropium Positioned in Step 3 and Step 4 Care for Asthma: Japanese Society of Allergology’s Revised Guidelines
June 5, 2015
- Pfizer Poised to Emerge as Global Leader in Oncology: Chief Medical Officer
June 3, 2015
- Xtandi Monotherapy Meets Primary Endpoint in PII Study for Triple-Negative Breast Cancer: Astellas
June 3, 2015
- 3 of 20 Japanese Gastric Cancer Patients Show PR to PD-L1 Inhibitor Avelumab: ASCO
June 3, 2015
- Ibrance Prolongs PFS in Second-Line for Advanced Breast Cancer: ASCO
June 3, 2015
- BBI608, BBI503 Exert Antitumor Activity in Multiple Studies: Sumitomo Dainippon
June 3, 2015
- Pfizer, Merck KGaA Set to Leverage Complementary Tie-Up to Develop PD-L1 Inhibitor
June 2, 2015
- Opdivo Shows OS Rate of 62% in HCC at 12 Months: ASCO
June 1, 2015
- MHLW-Funded Study Calls for Use-Based Development Plans for Combination Drugs
May 7, 2015
- Six Deaths Confirmed through Tofacitinib PMS, Guidelines Not Followed in All Cases
April 30, 2015
ページ
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…